Evaluation of in vitro storage characteristics of cold stored platelet concentrates with N acetylcysteine (NAC)

ROS scavenger, N‐acetyl‐l‐cysteine and NOX specific inhibitor, VAS2870 reduce platelets apoptosis while enhancing their viability during storage

“…One example is a study in which a much higher dose of NAC (50 mM) was applied to conclude that there was lower platelet activation and reduced sialidase activity in refrigerated PCs during cold storage. 25 Although the storage condition in this study is entirely different, considering the fact that such a high concentration of NAC may affect platelet viability, having less P-selectin expression in NAC-treated platelets must be interpreted with caution because it might be due to receptor shedding or membrane microvesiculation during platelet lesion. This highlights the rationale of our dose-dependent viability assay prior to conducting the main part of our study.…”

“…This may critically challenge the results obtained by others in which they applied the higher doses of NAC to achieve their research in the field of platelets, thrombosis, or transfusion medicine. One example is a study in which a much higher dose of NAC (50 mM) was applied to conclude that there was lower platelet activation and reduced sialidase activity in refrigerated PCs during cold storage . Although the storage condition in this study is entirely different, considering the fact that such a high concentration of NAC may affect platelet viability, having less P‐selectin expression in NAC‐treated platelets must be interpreted with caution because it might be due to receptor shedding or membrane microvesiculation during platelet lesion.…”

Manufacturing variables and hemostatic function of cold‐stored platelets: a systematic review of the literature

“…Seventeen of the short‐listed articles (52%) were collected as AP‐using devices manufactured by Gambro (one article), Haemonetics (three articles) and Terumo (nine articles), with no manufacturers identified in the remaining four articles . In the articles that reported use of APs, CSPs were collected into acid‐citrate‐dextrose (seven articles) . The remaining 10 AP articles did not specify an anticoagulant .…”

“…Of the 19 (58%) articles in which the CSP products were WBD, 10 (53%) articles were produced by buffy coat preparations, and nine (47%) were produced via platelet‐rich plasma (PRP) preparations . The predominant anticoagulant for WBD platelets was citrate–phosphate‐dextrose, which was reported in 10 (53%) articles (Table ) .…”

Refrigerated storage of platelets initiates changes in platelet surface marker expression and localization of intracellular proteins

“…Although deglycosylation and/or clustering of PLT glycoproteins have been shown to be involved in the clearance of refrigerated PLTs, preventing these changes appears insufficient to mitigate their clearance in humans, suggesting that other mechanisms may be involved. Along these lines, several recent studies have focused on whether adding inhibitors of PLT activation and apoptosis may improve PLT quality and prevent clearance …”